A Phase II, Open-label Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy in Males With Classic Fabry Disease Who Have Never Received Any Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Feb 2025 Status changed from recruiting to active, no longer recruiting as per AceLink Therapeutics media release
08 Feb 2025 According to a AceLink Therapeutics media release, AceLink completed enrollment of 18 patients across six sites in China in December 2024. Topline data from this Phase 2 trial is expected in Q3 2025.
08 Feb 2025 According to a AceLink Therapeutics media release, interim findings from this trial highlighted in a late-breaking oral platform presentation at the 2025 WORLD Symposium in San Diego, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com